Privacy Statement   Terms & Conditions   Sitemap  
  Diseases   Research   About us  
TBE Meningococcal Disease Influenza Smallpox
 
Disease

  Prophylaxis

For many years, the WHO has provided consultation services to examine the current influenza virus strains circulating worldwide and has recommended the appropriate vaccine composition to be used for the following season. The WHO strongly supports and encourages vaccine research based on tissue cultures and other methodologies due to the limited stock of fertilized chicken eggs for vaccine production. In case of a pandemic, this will be a limiting factor for the success of worldwide immunization campaigns. Baxter's special attention is therefore focused on the development of modern production technologies for influenza vaccines, such serum and protein free Vero cell technology like Vero cell lines.

 » Printversion

 
 
  » find


 

Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
» read more

Baxter receives preparedness contract from Austrian Ministry of Health for Pandemic Influenza Vaccine
» read more

Baxter Announces Safety and Immunogenicity Results from Phase I/II Clinical Trial of Cell-Based Candidate H5N1 Pandemic Vaccine
» read more

 
Baxter Vaccines Industriestrasse 67, A-1221 Wien, Tel: +43-1-20100,